DE102008045696A1 - Granulozyten HNA-3a/b-Antigen - Google Patents
Granulozyten HNA-3a/b-Antigen Download PDFInfo
- Publication number
- DE102008045696A1 DE102008045696A1 DE102008045696A DE102008045696A DE102008045696A1 DE 102008045696 A1 DE102008045696 A1 DE 102008045696A1 DE 102008045696 A DE102008045696 A DE 102008045696A DE 102008045696 A DE102008045696 A DE 102008045696A DE 102008045696 A1 DE102008045696 A1 DE 102008045696A1
- Authority
- DE
- Germany
- Prior art keywords
- hna
- sequence seq
- protein
- amino acid
- alloantibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000036639 antigens Human genes 0.000 title claims abstract description 54
- 108091007433 antigens Proteins 0.000 title claims abstract description 54
- 239000000427 antigen Substances 0.000 title claims abstract description 53
- 210000003714 granulocyte Anatomy 0.000 title description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 57
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 55
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 32
- 210000004369 blood Anatomy 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 210000002381 plasma Anatomy 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 5
- 208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 description 50
- 208000011580 syndromic disease Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 208000003441 Transfusion reaction Diseases 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- 206010037423 Pulmonary oedema Diseases 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 238000002616 plasmapheresis Methods 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 208000005333 pulmonary edema Diseases 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010066183 Febrile nonhaemolytic transfusion reaction Diseases 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000004023 fresh frozen plasma Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 238000010847 SEQUEST Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008045696A DE102008045696A1 (de) | 2008-09-04 | 2008-09-04 | Granulozyten HNA-3a/b-Antigen |
| AU2009289809A AU2009289809B2 (en) | 2008-09-04 | 2009-09-03 | Screening methods for transfusion related acute lung injury (TRALI) |
| CN200980144058.0A CN102203609B (zh) | 2008-09-04 | 2009-09-03 | 用于输血相关急性肺损伤(trali)的筛选方法 |
| BRPI0918233A BRPI0918233B8 (pt) | 2008-09-04 | 2009-09-03 | métodos de triagem para a lesão pulmonar aguda e doença do enxerto contra hospedeiro relacionada à transfusão ou transplante, kits e uso de polipeptídeos |
| JP2011525460A JP5766606B2 (ja) | 2008-09-04 | 2009-09-03 | 輸血関連急性肺障害（ｔｒａｌｉ）に関するスクリーニング方法 |
| PCT/EP2009/006386 WO2010025915A1 (en) | 2008-09-04 | 2009-09-03 | Screening methods for transfusion related acute lung injury (trali) |
| US12/553,487 US8084216B2 (en) | 2008-09-04 | 2009-09-03 | Screening methods for transfusion related acute lung injury (TRALI) |
| CA2735138A CA2735138C (en) | 2008-09-04 | 2009-09-03 | Screening methods for transfusion related acute lung injury (trali) |
| EP09778306.2A EP2321644B1 (en) | 2008-09-04 | 2009-09-03 | Screening methods for transfusion related acute lung injury (trali) |
| US13/306,380 US8435733B2 (en) | 2008-09-04 | 2011-11-29 | Screening methods for transfusion related acute lung injury |
| US13/845,898 US8999651B2 (en) | 2008-09-04 | 2013-03-18 | Screening methods for transfusion related acute lung injury (TRALI) |
| US14/678,827 US9963741B2 (en) | 2008-09-04 | 2015-04-03 | Screening methods for transfusion related acute lung injury (TRALI) |
| AU2016204135A AU2016204135A1 (en) | 2008-09-04 | 2016-06-17 | Screening methods for transfusion related acute lung injury (TRALI) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008045696A DE102008045696A1 (de) | 2008-09-04 | 2008-09-04 | Granulozyten HNA-3a/b-Antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102008045696A1 true DE102008045696A1 (de) | 2010-03-11 |
Family
ID=41266687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102008045696A Withdrawn DE102008045696A1 (de) | 2008-09-04 | 2008-09-04 | Granulozyten HNA-3a/b-Antigen |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US8084216B2 (https=) |
| EP (1) | EP2321644B1 (https=) |
| JP (1) | JP5766606B2 (https=) |
| CN (1) | CN102203609B (https=) |
| AU (2) | AU2009289809B2 (https=) |
| BR (1) | BRPI0918233B8 (https=) |
| CA (1) | CA2735138C (https=) |
| DE (1) | DE102008045696A1 (https=) |
| WO (1) | WO2010025915A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2162792A4 (en) | 2007-05-29 | 2011-08-24 | Lab Partners Associates Inc | SYSTEM AND METHOD FOR MAINTAINING FLASH CONTACT COMMUNICATIONS BETWEEN A CAMERA AND A WIRELESS DEVICE |
| WO2009114522A2 (en) * | 2008-03-10 | 2009-09-17 | Bonfils Blood Center | Compositions, kits and methods for determining etiology of trali and detecting patients at risk for this transfusion reaction |
| DE102008045696A1 (de) * | 2008-09-04 | 2010-03-11 | Drk Blutspendedienst West Ggmbh | Granulozyten HNA-3a/b-Antigen |
| WO2010059971A1 (en) * | 2008-11-21 | 2010-05-27 | Martin Heath Bluth | Diagnosing and monitoring response to treatment of non-incontinent urological and related diseases |
| WO2010065425A1 (en) | 2008-12-01 | 2010-06-10 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detection of complement fixing antibodies |
| US10101337B2 (en) | 2013-03-14 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of detecting donor-specific antibodies and systems for practicing the same |
| EP3140322B1 (en) * | 2014-05-09 | 2021-02-17 | One Lambda, Inc. | Modified fc gamma receptor type iii (fc iii, hna-1) polypeptides and the uses thereof |
| US10527613B2 (en) | 2015-11-10 | 2020-01-07 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarker detection methods and systems and kits for practicing same |
| WO2017094733A1 (ja) * | 2015-11-30 | 2017-06-08 | 日産化学工業株式会社 | 分子標的医薬に結合するｄｎａアプタマー及びそれを用いる分子標的医薬の検出方法 |
| AU2016402264B2 (en) * | 2016-04-15 | 2024-08-22 | Pontificia Universidad Católica De Chile | Pharmaceutical composition for reducing the symptoms and disease of the respiratory infection caused by human metapneumovirus (HMPV), which comprises at least one agent that neutralises the function of the TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, and the use thereof |
| CN116083551B (zh) * | 2022-10-11 | 2025-02-21 | 南宁中心血站(南宁输血医学研究所) | 用于检测人类中性粒细胞抗原基因分型的引物组合、试剂盒及方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10028725A1 (de) | 2000-06-09 | 2001-12-13 | Juergen Bux | Primärstruktur des HNA-2a (ehemals NB1)-Antigens |
| WO2007108368A1 (ja) * | 2006-03-23 | 2007-09-27 | Japanese Red Cross Society | 顆粒球抗体の検出に用いられるパネル細胞 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
| US20030082646A1 (en) | 1998-12-29 | 2003-05-01 | The Regents Of The University Of Michigan | Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL |
| CA2383592A1 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
| US6943235B1 (en) | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
| EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| FR2800750B1 (fr) | 1999-11-05 | 2003-01-31 | Centre Nat Rech Scient | Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030219777A1 (en) * | 2001-12-18 | 2003-11-27 | Lynx Therapeutics, Inc. | Identification of candidate genes for the atherosclerosis susceptibility locus (ATHS) |
| US7829292B2 (en) | 2002-05-06 | 2010-11-09 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| CA2516128A1 (en) * | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| US7303985B2 (en) | 2003-11-17 | 2007-12-04 | Intel Corporation | Zeolite-carbon doped oxide composite low k dielectric |
| DE102008045696A1 (de) * | 2008-09-04 | 2010-03-11 | Drk Blutspendedienst West Ggmbh | Granulozyten HNA-3a/b-Antigen |
-
2008
- 2008-09-04 DE DE102008045696A patent/DE102008045696A1/de not_active Withdrawn
-
2009
- 2009-09-03 CA CA2735138A patent/CA2735138C/en active Active
- 2009-09-03 AU AU2009289809A patent/AU2009289809B2/en active Active
- 2009-09-03 WO PCT/EP2009/006386 patent/WO2010025915A1/en not_active Ceased
- 2009-09-03 US US12/553,487 patent/US8084216B2/en active Active
- 2009-09-03 EP EP09778306.2A patent/EP2321644B1/en active Active
- 2009-09-03 CN CN200980144058.0A patent/CN102203609B/zh active Active
- 2009-09-03 JP JP2011525460A patent/JP5766606B2/ja active Active
- 2009-09-03 BR BRPI0918233A patent/BRPI0918233B8/pt active IP Right Grant
-
2011
- 2011-11-29 US US13/306,380 patent/US8435733B2/en active Active
-
2013
- 2013-03-18 US US13/845,898 patent/US8999651B2/en active Active
-
2015
- 2015-04-03 US US14/678,827 patent/US9963741B2/en active Active
-
2016
- 2016-06-17 AU AU2016204135A patent/AU2016204135A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10028725A1 (de) | 2000-06-09 | 2001-12-13 | Juergen Bux | Primärstruktur des HNA-2a (ehemals NB1)-Antigens |
| WO2007108368A1 (ja) * | 2006-03-23 | 2007-09-27 | Japanese Red Cross Society | 顆粒球抗体の検出に用いられるパネル細胞 |
Non-Patent Citations (26)
| Title |
|---|
| Boshkov, L. K (2002): Transfusion-associated acute lung injury: An evolving understanding of the roles of leukocyte antibodies. Vox Sang 83: 299-303 |
| Bux, J., Becker, F., Seeger, W., Kilpatrick, D., Chatman, J., and Waters, A. (1996) Transfusion related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blond. BrJ Heamatol. 93: 707-713 |
| Davoren, A., Curtis, B. R., Shulman, I. A., Mohrbacher, A. F., Bux, J., Kwiatkowska, B. J., McFarland, J. G., and Aster, R. H. (2003) TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion 43: 641-645 |
| Densmore, T. L., Goodnough, L. T., Ali, S., Dynis, M., and Chaplin, H. (1999) Prevalence of HLA sensitization in female apheresis donors. Transfusion 39: 103-106 |
| Goldman, M., Webert, K. E., Arnold, D. M., Freedman, J., Hannon, J., and Blajchman, M. A. (2005) Proceedings of a consensus conference: Towards an understanding of TRALI. Transfus Med Rev 19: 2-31 |
| Holness, L., Knippen, M. A., Simmons, L., and Lachenbruch, P. A. (2004) Fatalities caused by TRALI. Transfus Med Rev. 18: 184-188 |
| Internet-Recherche am 14.07.2009: www.interscience.wiley.com/ journal, BUX,J.: Human neutrophil alloantigens, 16.01.2008 * |
| Internet-Recherche am 14.07.2009: www.ncbi.nlm.gov/sites/entrez? CTL2 Protein, Accession Nummer: XP_001165902, 16.09.2006 * |
| Internet-Recherche am 14.07.2009: www.ncbi.nlm.gov/sites/entrez? CTL2 Protein, Accession Nummer: XP_001165902, 16.09.2006 Sequenzvergleich der Sequenz SEQ ID NO 1 mit XP_001165902 Sequenzvergleich der Sequenz SEQ ID NO 2 mit XP_001165902 Internet-Recherche am 14.07.2009: www.ncbi.nlm.gov/sites/entrez? Protein aus dem Menschen Accession, Nummer: BAC11662, 09.01.2008 Sequenzvergleich der Sequenz SEQ ID NO 2 mit BAC11662 Internet-Recherche am 14.07.2009: www.interscience.wiley.com/ journal, BUX,J.: Human neutrophil alloantigens, 16.01.2008 Internet-Recherche am 16.07.2009: www.pasteur.fr/recherche/RAR, BEGUIN,P.: Production of monoclonal antibodies and recombinant proteins (Platform). 2005 |
| Internet-Recherche am 14.07.2009: www.ncbi.nlm.gov/sites/entrez? Protein aus dem Menschen Accession, Nummer: BAC11662, 09.01.2008 * |
| Internet-Recherche am 16.07.2009: www.pasteur.fr/recherche/RAR, BEGUIN,P.: Production of monoclonal antibodies and recombinant proteins (Platform). 2005 * |
| Kopko, P. M., Marshall, C. S., Mackenzie, M. R., Holland, P. V., and Popovsky, M. A. (2002) Transfusion-related acute lung injury. Report of a clinical look-back investigation. JAMA 287:1968-1971 |
| Leger, R., Palm, S., Wulf, H., Vosberg, A., and Neppert, J. (1999) Transfusion related acute lung injury with leukopenic reaction caused by fresh frozen plasma containing anti-NB1. Anesthesiology 91: 1529-1532 |
| Mair, D. C., Hirschler, N., and Eastlund, T. (2006) Blood donor and component management strategies to prevent transfusion-related acute lung injury (TRALI). Crit Care Med. 34: 137-143 |
| Popovsky, M. A. & Moore, S. B. (1985) Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 25: 573-577 |
| Reil, A., Keller-Stanislawski, B., Günay, S. and Bux, J. (2008) Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blond donors. Vox Sanguinis (im Druck, online bereits zugänglich) |
| Reil, A., Keller-Stanislawski, B., Günay, S. and Bux, J. (2008) Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sanguinis (im Druck, online bereits zugänglich) |
| Saigo, K., Sugimoto, T., Tone, K., Ryo, R., Kohsaki, M., Tadokoro, K., and Kumagai, S. (1999) Transfusion-related acute lung injury in a patient with acute myelogenous leukaemia having anti-IgA2m(1) antibody. J Int Med Res. 27: 96-100 |
| Sequenzvergleich der Sequenz SEQ ID NO 1 mit XP_001165902 * |
| Sequenzvergleich der Sequenz SEQ ID NO 2 mit BAC11662 * |
| Sequenzvergleich der Sequenz SEQ ID NO 2 mit XP_001165902 * |
| Snyder, E. L. (1995) The role of cytokines and adhesive molecules in febrile non-hemolytic transfusion reactions. Immunol Invest. 24: 333-9 |
| Uchiyama, H., Anderson, K. C. (1994) Cellular adhaesion molecules. Transfus Med rev 8: 84-95 |
| Voss, J., Westphal, K., Bohme, J., Bux, J., and Greinacher, A. (2001) Das TRALI-Syndrom, Eine lebensbedrohliche Transfusionsreaktion. Anaesthesist 50: 930-932 |
| www.ehn-org.net |
| www.shotuk.org |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150203915A1 (en) | 2015-07-23 |
| EP2321644B1 (en) | 2016-12-14 |
| JP2012501631A (ja) | 2012-01-26 |
| BRPI0918233B1 (pt) | 2020-12-01 |
| US20120070834A1 (en) | 2012-03-22 |
| CN102203609B (zh) | 2017-07-11 |
| US8084216B2 (en) | 2011-12-27 |
| US20100055706A1 (en) | 2010-03-04 |
| BRPI0918233A2 (pt) | 2015-12-15 |
| CA2735138A1 (en) | 2010-03-11 |
| CN102203609A (zh) | 2011-09-28 |
| WO2010025915A1 (en) | 2010-03-11 |
| AU2009289809A8 (en) | 2011-05-12 |
| US20130189696A1 (en) | 2013-07-25 |
| US8999651B2 (en) | 2015-04-07 |
| US8435733B2 (en) | 2013-05-07 |
| EP2321644A1 (en) | 2011-05-18 |
| BRPI0918233B8 (pt) | 2021-07-27 |
| CA2735138C (en) | 2021-06-01 |
| US9963741B2 (en) | 2018-05-08 |
| AU2009289809A1 (en) | 2010-03-11 |
| AU2016204135A1 (en) | 2016-07-14 |
| AU2009289809B2 (en) | 2016-07-07 |
| JP5766606B2 (ja) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE102008045696A1 (de) | Granulozyten HNA-3a/b-Antigen | |
| DE60019111T2 (de) | Verfahren zur zellseparation unter verwendung von immunorosetten | |
| DE69501161T2 (de) | Verfahren zum nachweis und/oder zur bestimmung und/oder zur isolierung von apoptotischen zellen in oder aus einer probe | |
| DE3650184T2 (de) | Zellenfreier t-zellenantigenrezeptor und klinische verwendung. | |
| Bukovsky et al. | Placental expression of estrogen receptor beta and its hormone binding variant–comparison with estrogen receptor alpha and a role for estrogen receptors in asymmetric division and differentiation of estrogen-dependent cells | |
| Griffin et al. | Mass spectrometry reveals distinct proteomic profiles in high-and low-quality stallion spermatozoa | |
| JP2021509475A (ja) | 外傷性脳損傷を診断及び査定するための、新規のバイオマーカー及び方法 | |
| DE60114018T2 (de) | Von zellen präsentierte peptide | |
| AT500379A2 (de) | Tau-proteine | |
| EP3505935B1 (de) | Verfahren zur diagnose einer bornavirus-infektion | |
| EP0584715A2 (de) | Gewinnung und Kultivierung transformierter Zellen und Herstellung gegen sie gerichteter Antikörper | |
| Hata et al. | Alternative processing of γ‐secretase substrates in common forms of mild cognitive impairment and Alzheimer's disease: evidence for γ‐secretase dysfunction | |
| EP1301798A2 (de) | Schonende hochanreicherung von fetalen zellen aus peripherem blut und verwendung derselben | |
| DE19918141A1 (de) | Verfahren zur Diagnose von übertragbaren Spongiformen Enzephalopathien | |
| DE69933679T2 (de) | Darstellung des profils und katalogisierung von exprimierten proteinmarkern | |
| Paltrinieri et al. | Influence of age and foaling on plasma protein electrophoresis and serum amyloid A and their possible role as markers of equine neonatal septicaemia | |
| DE3879085T2 (de) | Snrnp-a-antigen und fragmente davon. | |
| DE19727814C1 (de) | Anitkörper 4G8B4B12 | |
| DE69717991T2 (de) | Ein monoklonaler antikörper, welcher ein apoptotisches antigen nachweist | |
| CH685959A5 (de) | Diagnostische Testpackung zur Bestimmung von Proteinen. | |
| DE10122806A1 (de) | Verfahren zum Nachweis von Blutzell-Antigenen und gegen diese gerichtete Antikörper | |
| DE69510668T2 (de) | Verfahren zum nachweis von endprodukten der fortgeschrittenen glykosylierung von hämoglobin | |
| Dominique Le Lann et al. | In vitro inhibition of natural-killer-mediated lysis by chromatin fragments | |
| van Megen et al. | Alterations of muscarinic acetylcholine receptors in the nasal mucosa of allergic patients in comparison with nonallergic individuals | |
| DE68926245T2 (de) | Nachweis der basismembrankomponenten, diagnose von krebs und sonstigen krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| R120 | Application withdrawn or ip right abandoned |